SE503236C2 - Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit - Google Patents

Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit

Info

Publication number
SE503236C2
SE503236C2 SE8804036A SE8804036A SE503236C2 SE 503236 C2 SE503236 C2 SE 503236C2 SE 8804036 A SE8804036 A SE 8804036A SE 8804036 A SE8804036 A SE 8804036A SE 503236 C2 SE503236 C2 SE 503236C2
Authority
SE
Sweden
Prior art keywords
manufacture
psoriasis
test
atopic dermatitis
azatricyclo
Prior art date
Application number
SE8804036A
Other languages
English (en)
Swedish (sv)
Other versions
SE8804036D0 (sv
SE8804036L (sv
Inventor
Maximilian Grassberger
Josef Gottfried Meingassner
Anton Stuetz
Peter Stuetz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25599336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE503236(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AT0295287A external-priority patent/AT400808B/de
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8804036D0 publication Critical patent/SE8804036D0/xx
Publication of SE8804036L publication Critical patent/SE8804036L/
Publication of SE503236C2 publication Critical patent/SE503236C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE8804036A 1987-11-09 1988-11-08 Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit SE503236C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0295287A AT400808B (de) 1987-11-09 1987-11-09 Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
DE3742805 1987-12-17

Publications (3)

Publication Number Publication Date
SE8804036D0 SE8804036D0 (sv) 1988-11-08
SE8804036L SE8804036L (sv) 1989-05-10
SE503236C2 true SE503236C2 (sv) 1996-04-22

Family

ID=25599336

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8804036A SE503236C2 (sv) 1987-11-09 1988-11-08 Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit
SE9402558A SE519137C2 (sv) 1987-11-09 1994-07-22 Ny användning av azatricykloderivat och farmaceutiska kompositioner innehållande desamma

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9402558A SE519137C2 (sv) 1987-11-09 1994-07-22 Ny användning av azatricykloderivat och farmaceutiska kompositioner innehållande desamma

Country Status (13)

Country Link
US (1) US20050059694A1 (ja)
EP (2) EP0596541B1 (ja)
JP (1) JP2604834B2 (ja)
KR (1) KR0133916B1 (ja)
AU (1) AU619772B2 (ja)
CH (1) CH677448A5 (ja)
CY (1) CY1730A (ja)
DK (1) DK175235B1 (ja)
GB (1) GB2212061B (ja)
HK (1) HK8694A (ja)
NL (1) NL195077C (ja)
PH (1) PH26083A (ja)
SE (2) SE503236C2 (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5519049A (en) * 1989-06-06 1996-05-21 Fisons Plc Macrolides for the treatment of reversible obstructive airways diseases
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
EP0406791B1 (en) * 1989-07-05 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Aqueous liquid composition for external use
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
JPH05504956A (ja) * 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
EP0455427A1 (en) * 1990-04-30 1991-11-06 Merck & Co. Inc. Deoxymacrolide derivatives having immunosuppressive activity
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
GB9218597D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
KR100434682B1 (ko) 1994-10-26 2004-08-18 노바티스 아게 약학조성물
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2004069247A1 (en) * 2003-02-06 2004-08-19 Cipla Ltd Topical immunotherapy and compositions for use therein
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
WO2010041684A1 (ja) 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139563A (en) * 1977-07-01 1979-02-13 Merrell Toraude Et Compagnie α-ACETYLENIC DERIVATIVES OF AMINES
DE2964567D1 (en) * 1978-12-21 1983-02-24 Lepetit Spa New 3h-naphtho(1,2-d)imidazoles, processes for preparing them, compounds for use as antiinflammatory and antimicrobial agents and compositions for that use containing them
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
US4556654A (en) * 1983-06-28 1985-12-03 Warner-Lambert Company Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3

Also Published As

Publication number Publication date
HK8694A (en) 1994-02-04
GB2212061B (en) 1991-08-28
SE9402558D0 (sv) 1994-07-22
GB2212061A (en) 1989-07-19
US20050059694A1 (en) 2005-03-17
SE519137C2 (sv) 2003-01-21
EP0315978A3 (en) 1990-06-13
SE8804036D0 (sv) 1988-11-08
JP2604834B2 (ja) 1997-04-30
CY1730A (en) 1994-05-06
EP0315978B1 (en) 1994-10-26
CH677448A5 (ja) 1991-05-31
EP0315978A2 (en) 1989-05-17
DK175235B1 (da) 2004-07-19
DK620388D0 (da) 1988-11-07
AU619772B2 (en) 1992-02-06
NL195077C (nl) 2003-07-23
PH26083A (en) 1992-02-06
SE8804036L (sv) 1989-05-10
NL8802734A (nl) 1989-06-01
AU2490288A (en) 1989-05-11
GB8826066D0 (en) 1988-12-14
KR890007736A (ko) 1989-07-05
DK620388A (da) 1989-05-10
EP0596541A1 (en) 1994-05-11
KR0133916B1 (ko) 1998-04-22
EP0596541B1 (en) 2000-03-15
JPH01157913A (ja) 1989-06-21

Similar Documents

Publication Publication Date Title
SE503236C2 (sv) Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit
US11318113B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
KR100299394B1 (ko) 면역염증성질환치료용약제학적조성물
US9173920B2 (en) Methods of treating muscular wasting diseases using NF-KB activation inhibitors
Xiao et al. Possible treatment for UVB-induced skin injury: anti-inflammatory and cytoprotective role of metformin in UVB-irradiated keratinocytes
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
JP2016534091A (ja) 尋常性ざそうを治療するためのアセチル−ＣｏＡカルボキシラーゼ阻害薬の使用
KR20050021464A (ko) 피부병의 국소 치료
EP2389180A1 (en) Methods of treating muscular dystrophies
US5665727A (en) Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
Campo et al. RETRACTED: Purified human plasma glycosaminoglycans reduced NF-κB activation, pro-inflammatory cytokine production and apoptosis in LPS-treated chondrocytes
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
Hegemann et al. Effects of tiflucarbine as a dual protein kinase C/calmodulin antagonist on proliferation of human keratinocytes and release of reactive oxygen species from human leukocytes
CN113521071A (zh) 氯喹那多的新应用
WO2004096222A1 (en) Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
US7074938B2 (en) Method for the synthesis of soritin compounds
Ban et al. Molecular mechanisms involved in the antiproliferative action of protein tyrosine phosphatase inhibitor potassium bisperoxo (1, 10-phenanthroline) oxovanadate
US20080004235A1 (en) Topical compositions comprising one or more of 4-thiouridine, isomaltitol and uridine
CN116949169B (zh) Smek1在缺血性脑卒中诊治中的应用
Kameda et al. Irsogladine Inhibits Ionomycin-Induced Decrease in Intercellular Communication in Cultured Rabbit Gastric Epithelial Cells.
DE3838035C2 (de) Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
Ockenfels et al. Inhibition of T cell cAMP formation by cyclosporin A and FK506
US20030166516A1 (en) Methods of treating, preventing, or inhibiting inflammation with exumolide compounds